Patent No. 7,928,062

Description:
This patent relates to inhibition of proliferation and function of lymphocytes and other cells of lymphoid origin which contain the Janus tyrosine kinase (Jak3). More particularly This patent relates to therapeutic and testing methods using chemical agents which block lymphocyte function, especially regulation of immune activity. Still more particularly, This patent relates to selectively disrupting Janus tyrosine kinase 3 (Jak3) mediated cell activities and cell proliferation.

Abstract:
Methods are disclosed for inhibiting or disrupting Janus tyrosine kinase 3 (Jak3) dependent function in cells of lymphoid or myeloid origin, especially for blocking proliferation and function of lymphocytes (e.g., T-cells, B-cells). A Mannich base compound, or a derivative or modified compound, is employed which is capable of selectively inhibiting Jak3 while affecting other protein tyrosine kinase activities to a lesser extent or not at all, to provide beneficial effects such as mitigation of transplant rejection and alleviation of allergic responses with fewer side effects than with conventional immunosuppressive agents.


UTEP Docket No: 2006-769